HIF-1α in myocardial ischemia-reperfusion injury

Myocardial ischemia-reperfusion injury (MIRI) is a severe injury to the ischemic myocardium following the recovery of blood flow. Currently, there is no effective treatment for MIRI in clinical practice. Over the past two decades, biological studies of hypoxia and hypoxia-inducible factor-1 alpha (HIF-1 alpha) have notably improved understanding of oxygen homeostasis. HIF-1 alpha is an oxygen-sensitive transcription factor that mediates adaptive metabolic responses to hypoxia and serves a pivotal role in MIRI. In particular, previous studies have demonstrated that HIF-1 alpha improves mitochondrial function, decreases cellular oxidative stress, activates cardioprotective signaling pathways and downstream protective genes and interacts with non-coding RNAs. The present review summarizes the roles and associated mechanisms of action of HIF-1 alpha in MIRI. In addition, HIF-1 alpha-associated MIRI intervention, including natural compounds, exosomes, ischemic preconditioning and ischemic post-processing are presented. The present review provides evidence for the roles of HIF-1 alpha activation in MIRI and supports its use as a therapeutic target.

Automated summary

HIF-1 alpha plays a crucial role in myocardial ischemia-reperfusion injury by improving mitochondrial function, reducing oxidative stress, activating protective signaling pathways, and interacting with non-coding RNAs. Studies support the activation of HIF-1 alpha as a therapeutic target for MIRI intervention.